Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS015 in Advanced Solid Tumors
NCT05770310Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JS015 in solid tumor, sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 2 years, Adverse Events at 2 years and 3 more. Started Feb 2023; status: completed.
02
Drugs
JS015
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05770310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05770310.